Findings from a landmark survey have revealed that people with experience using psychedelics exhibited elevated psychological well-being during the COVID-19 pandemic.
A new survey study carried out by The Beckley Foundation and Maastricht University has found that classical psychedelics such as psilocybin and LSD could have painkilling...
Jazz Pharmaceuticals, a leading global biopharmaceutical company, recorded an astonishing $1.8 billion in revenue this year from the sales of Gamma Hydroxybutyrate (GHB).
Johns Hopkins University School of Medicine (JHU) and Clearmind Medicine will be collaborating on research to investigate the use of a novel psychoactive molecule to treat...
Awakn Life Sciences has submitted a clinical trial application to investigate the use of AWKN-P001 – a novel combined therapeutic of an N-methyl-D-aspartate receptor-modulating drug (ketamine)...
In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in...
A new study investigating a single dose of psilocybin for the treatment of major depressive disorder (MDD) has shown clinically significant levels of reduction in depressive...
Japanese pharmaceutical company Otsuka Pharmaceutical has made one of Big Pharma’s first pivots into the psychedelics space with the acquisition of Mindset Pharma.
A new study has shown how trained human coders were able to identify observable markers of therapeutic connection during psilocybin administration in psychedelic-assisted therapy.
Launching in 2008 as a drug literature review blog by Rob Dickins, Psychedelic Press has brought readers a host of unique insights into psychedelic thought and...
Cybin Inc.
atai Life Sciences has announced results from its Phase 1 Study of DMX-1002 (Ibogaine) for the treatment of opioid use disorder (OUD).